In Brief
Natural Ebola virus infection causes the induction of B cells that encode potent neutralizing human antibodies, which possess, in some cases, a surprising level of cross-reactivity for multiple species of filoviruses. The neutralizing antibody repertoire recognizes diverse features on the surface glycoprotein, but most of the potent antibodies recognize the glycan cap region.
SUMMARY
Recent studies have suggested that antibody-mediated protection against the Ebolaviruses may be achievable, but little is known about whether or not antibodies can confer cross-reactive protection against viruses belonging to diverse Ebolavirus species, such as Ebola virus (EBOV), Sudan virus (SUDV), and Bundibugyo virus (BDBV). We isolated a large panel of human monoclonal antibodies (mAbs) against BDBV glycoprotein (GP) using peripheral blood B cells from survivors of the 2007 BDBV outbreak in Uganda. We determined that a large proportion of mAbs with potent neutralizing activity against BDBV bind to the glycan cap and recognize diverse epitopes within this major antigenic site. We identified several glycan cap-specific mAbs that neutralized multiple ebolaviruses, including SUDV, and a cross-reactive mAb that completely protected guinea pigs from the lethal challenge with heterologous EBOV. Our results provide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus infections.
INTRODUCTION
The genus Ebolavirus, family Filoviridae, contains three viral species that are known to cause large deadly disease outbreaks in Africa: Zaire ebolavirus represented by Ebola virus (EBOV), Sudan ebolavirus represented by Sudan virus (SUDV), and Bundibugyo ebolavirus represented by Bundibugyo virus (BDBV). The most recent EBOV outbreak has caused more than 28,000 cases and more than 11,000 deaths (according to the October 14, 2015, World Health Organization [WHO] Ebola Situation Report). While there is no FDA-approved treatment for filovirus infections, several experimental therapeutics against EBOV are being investigated, including small interfering RNAs (Geisbert et al., 2010; Thi et al., 2015) , antisense oligonucleotides (Warren et al., 2010 (Warren et al., , 2015 , a nucleoside analog (Warren et al., 2014) , therapeutic vaccines (Feldmann et al., 2007; Geisbert et al., 2008) , and monoclonal antibody (mAb) cocktails (Olinger et al., 2012; Qiu et al., 2012 Qiu et al., , 2014 . Of these, preliminary treatment studies suggest that the effect of the ZMapp mAb cocktail exceeded the efficacy and treatment window of other experimental therapeutics described so far .
The ZMapp cocktail is composed of three EBOV glycoprotein (GP)-specific mAbs (designated c13C6, c2G4, and c4G7) that were isolated initially from mice (Qiu et al., 2011; Wilson et al., 2000) , chimerized with human antibody-constant regions, and then produced in Nicotiana benthamiana . Single-particle electron microscopy (EM) reconstructions of these mAbs in complex with EBOV surface protein have revealed key sites of vulnerability on the EBOV GP (Murin et al., 2014) . One such site lies within the GP base at the GP1/GP2 interface; two of three mAbs from the ZMapp cocktail (c2G4 and c4G7) bind to overlapping epitopes located in this region. The third mAb from the ZMapp cocktail, c13C6, binds a second antigenic site, which is located in the glycan cap region. GP base regionspecific mAbs c2G4 and c4G7 displayed high neutralization activity in vitro (IC 50 < 0.1 mg/ml), whereas the glycan cap-specific mAb c13C6 weakly neutralized EBOV only in the presence of complement (IC 50 > 1.0 mg/ml) . The lower in vitro neutralization activity of glycan cap-specific antibodies may be due to the removal of the glycan cap by host proteases (Chandran et al., 2005; Cô té et al., 2011; Misasi et al., 2012) inside the endosome before GP engagement with the NiemannPick C1 receptor (Carette et al., 2011; Cô té et al., 2011) . The ability of mAbs to bind to conserved neutralizing epitopes present on the surface of highly variable viral proteins has been documented extensively for HIV (Burton et al., 2012) , influenza viruses (Pappas et al., 2014) , dengue virus (Rouvinski et al., 2015) , paramyxoviruses (Corti et al., 2013) , and alphaviruses (Fox et al., 2015) . Despite similar requirements for virus entry into the cell (Misasi et al., 2012) , GPs from BDBV, EBOV, and SUDV strains differ by over 30% at the amino acid level (Towner et al., 2008) . This overall genetic divergence among species of genus Ebolavirus has hampered the development of ebolavirus cross-neutralizing Abs. The key components of multiple antibody cocktails developed over the last decade neutralize only viruses of species Zaire ebolavirus. A weakly neutralizing mAb c13C6 was shown to cross-react with SUDV GPs (Wilson et al., 2000) , but it is unknown whether this mAb can neutralize SUDV. Recently, several studies have shown that cross-reactive antibodies in serum can be elicited during natural infection in humans or vaccination of animals. The serum of individuals who survived BDBV, EBOV, or SUDV infections contained ebolavirus cross-reactive IgG, but not IgM (Macneil et al., 2011) . Other studies demonstrated that mice immunized with a vaccine bearing the GP of EBOV generated cross-reactive polyclonal mAbs to other ebolaviruses, such as BDBV and SUDV (Meyer et al., 2015; Ou et al., 2012) . Four broadly reactive non-neutralizing mAbs were isolated in mice after vaccinating animals with recombinant vesicular stomatitis virus (rVSV) expressing EBOV GP and then boosting initial immune response with the heterologous virus containing SUDV GP (Hernandez et al., 2015) . The epitopes recognized by such cross-reactive mAbs are unknown.
In this study, we isolated a large panel of BDBV-specific and ebolavirus cross-reactive mAbs from B cells of survivors of BDBV infection. The results show that a large proportion of mAbs with potent neutralizing activity against BDBV bind to the glycan cap and recognize diverse epitopes within this major antigenic site. We identified several glycan cap-specific mAbs that neutralized multiple Ebolavirus species and a cross-reactive mAb that completely protected guinea pigs from the lethal challenge with heterologous EBOV when used as monotherapy. Several of these naturally occurring antibodies exhibit the most potent protective capacity reported, and they possessed unprecedented cross-reactivity for multiple Ebolavirus species, including SUDV, for which neutralizing human mAbs have not been reported.
RESULTS

Isolation of Human mAbs
To generate human cell lines secreting human mAbs to BDBV, we transformed peripheral blood B cells from seven survivors of the 2007 Uganda BDBV outbreak with Epstein-Barr virus, as described in the Experimental Procedures. To determine the breadth of antibody response in survivors of ebolavirus infection, we screened supernatants from EBV-transformed B cell lines for binding to GPs from diverse representatives of filovirus species: BDBV, EBOV, or Marburg virus (MARV) ( Figures 1A and S1 ). We also used the same GP panel to screen supernatants from transformed B cell lines derived from a survivor of the 2014 EBOV outbreak ( Figure 1B) or from a donor who survived MARV infection ( Figure 1C ). We color coded GP-reactive supernatants based on the cross-reactivity pattern as follows: species-specific cell lines are highlighted in black; and cross-reactive lines to two or three species are shown in yellow or blue, respectively .
While approximately half of GP-specific B cell lines obtained from BDBV survivors produced antibodies specific to BDBV GP, 24%-50% of GP-reactive B cell culture supernatants also cross-reacted with EBOV GP (Figures 1A and 1D) . Similarly, 36% of GP-specific B cell lines obtained from the EBOV survivor cross-reacted with the heterologous BDBV GP ( Figures 1B and  1D ). Despite the apparent presence of B cells encoding crossreactive antibodies in survivors of BDBV or EBOV infections to GPs from heterologous Ebolavirus species, we detected a very limited cross-reactivity with GPs from MARV, which belongs to a different genus in the family Filoviridae ( Figures 1A and 1D ). In line with this finding, 90% of GP-reactive B cell lines obtained from the MARV survivor reacted with autologous GP, and only 2% of antigen-specific B cell lines produced Ebolavirus crossreactive Abs ( Figures 1C and 1D ). The limited cross-reactivity of mAbs to GPs from Ebolavirus and Marburgvirus species likely is due in part to low sequence conservation between GPs from two genera (only 27% amino acid identity between BDBV and MARV GP) as well as differences in epitope availability caused by different positions of the mucin-like domains on the GP surface of Ebolavirus and Marburgvirus Fusco et al., 2015; Hashiguchi et al., 2015) .
Binding and Neutralizing Activity of Human mAbs
We fused transformed cells from B cell lines producing BDBV GP-reactive Abs with myeloma cells and generated 90 cloned hybridomas secreting BDBV GP-reactive human mAbs. To determine the breadth of mAb binding, we screened the mAbs (legend continued on next page)
in ELISA-binding assays using recombinant GPs from multiple filoviruses: BDBV, EBOV, SUDV, or MARV GPs. While 33 Abs recognized only the autologous BDBV GP (designated groups 1A and 1B), 20 Abs recognized both BDBV and EBOV GPs (groups 2A and 2B), and 37 Abs recognized all three GPs from BDBV, EBOV, and SUDV (groups 3A and 3B) (Figures 2A and  2C ; Data S1). The relative proportions of antibodies that recognize GPs from 1, 2, or 3 Ebolavirus species did not correlate fully with the B cell line frequencies in the initial screen, which can be explained by our prioritization on recovery of a high number of cross-reactive mAbs. We were not able to isolate Abs that bind to the heterologous MARV GP (Figures 2A and 2C ; Data S1). We further characterized the binding of species-specific or cross-reactive mAbs to recombinant GPs by performing a binding assay with the recombinant form of GP that is secreted from the cell to the extracellular space during natural infection (sGP, secreted GP) (Sanchez et al., 1996; Volchkov et al., 1995) . While the Ebolavirus GP is a trimer, sGP forms dimers in which each protomer shares only the amino-terminal 295 amino acids with GP. The majority of mAbs recognized epitopes shared between BDBV GP and BDBV sGP (designated groups 1A, 2A, or 3A) (Figures 2A and 2C) . We also identified antibodies that bound to BDBV GP, but failed to bind BDBV sGP in ELISA (designated groups 1B, 2B, or 3B) (Figures 2A and 2C ). Antibodies from groups 1B, 2B, or 3B also bound the recombinant GP form that lacks highly glycosylated mucin-like domains (BDBV GPDmuc), suggesting that mAbs from these three groups target epitopes outside of mucin-like domains ( Figure S2 ).
To evaluate the inhibitory activity of isolated mAbs, we tested mAbs in a BDBV neutralization assay. Of the 90 BDBV GP-reactive mAbs, 31 had half-maximal inhibitory concentration (IC 50 ) values <10 mg/ml, and we defined these as neutralizing antibodies (nAbs) (Figures 2B, where nAb names are highlighted in red, and S3). Several nAbs displayed an extremely high neutralizing potency, with IC 50 values below 1 ng/ml ( Figure 2B ). Also, 18 of 31 nAbs bound only to BDBV GP in ELISA, six nAbs recognized BDBV and EBOV GPs, and the remaining seven nAbs bound to GPs from representatives of three Ebolavirus species, BDBV, EBOV, and SUDV. These results suggested that crossreactive mAbs in our panel might possess neutralizing activity to multiple ebolaviruses. To test this hypothesis, we screened BDBV425 (a group 2A nAb) in an EBOV neutralization assay as the nAb with the lowest half-maximal effective concentration (EC 50 ) value to the heterologous EBOV GP, and we determined that BDBV425 neutralized the heterologous EBOV. Encouraged by this result, we tested nAbs from groups 3A and 3B in EBOV or SUDV neutralization assays to determine whether cross-reactive nAbs can neutralize three Ebolavirus species. We found two cross-reactive nAbs from group 3A (BDBV43 and BDBV324) that neutralized all three ebolaviruses BDBV, EBOV, and SUDV ( Figure 2D , BDBV43). The remaining five nAbs from groups 3A and 3B neutralized BDBV and EBOV, but failed to neutralize SUDV ( Figure 2D , BDBV289). Analysis of the Ab heavy-chain variable domain sequences for 26 nAbs revealed that all BDBV-specific and cross-reactive nAbs were encoded by unique Ab genes (Table S1 ).
Major Antigenic Sites Recognized by Human mAbs
To determine whether Abs from distinct binding groups targeted different antigenic regions on the BDBV GP surface, we performed a quantitative competition-binding assay using a realtime biosensor. We tested four BDBV nAbs from binding group 1A, five nAbs from binding group 1B, four nAbs from group 3A, and three nAbs from group 3B in a tandem blocking assay, in which BDBV GP was attached to the biosensor. We also tested five non-neutralizing antibodies from group 1A to determine whether non-neutralizing antibodies target a unique epitope on GP surface. Non-neutralizing and neutralizing mAbs from group 1A and nAbs from group 3A blocked binding of each other to the GP antigen and segregated into a single competition-binding group (Figure 3) . These results suggest that mAbs from groups 1A and 3A target a single antigenic region that contains epitopes shared between GP and sGP ( Figure 2A ). The nAbs from group 3B that did not recognize sGP in ELISA (Figure 2A ) segregated into a separate competition-binding group. Group 1B antibodies were interesting in that two nAbs in this group competed for binding with group 3B nAbs, while three nAbs from the group competed for binding with antibodies from group 3A (Figure 3 ). These findings suggested that there are at least two major antigenic regions recognized by human BDBV nAbs, based on competition-binding studies. The first major antigenic region contains epitopes that both sGP and GP share (recognized by mAbs from groups 1A and 3A) as well as epitopes that are present only on the GP surface (recognized by three mAbs from group 1B). The second major antigenic region contains only epitopes that are present on the GP surface, but not sGP (recognized by two mAbs from group 1B and three mAbs from group 3B).
Diverse Patterns of Molecular Recognition Defined by Negative-Stain EM
To determine the location of the two major antigenic regions targeted by human BDBV nAbs, we performed negative-stain single-particle EM studies using antibodies from groups 1A and 1B. The EM class averages and reconstructions showed clearly that the two major antigenic regions, defined in competition-binding experiments, corresponded to two distinct sites on the GP surface: the glycan cap and the GP base.
Comparison of the structures of glycan cap-directed mAbs from group 1A with those in group 1B revealed that the antibodies have partially overlapping epitopes, but approach the glycan cap at distinct angles ( Figures 4A, 4B , and S4). We fitted a previously determined atomic resolution structure of SUDV GPDmuc (Bale et al., 2012) , which reveals more residues of the (C) Binding of representative mAbs from six distinct binding groups to the filovirus GPs is shown. (D) Neutralization activity of representative neutralizing mAbs from three binding groups against BDBV, EBOV, or SUDV. Error bars represent the SE of the experiment, performed in triplicate. See also Table S1 , Data S1, and Figures S2 and S3. glycan cap region than the equivalent EBOV structure, into the envelope of GP from the EM reconstructions, and we determined the regions targeted by each mAb (Figures 4D and 4E) . BDBV335, which binds GP and sGP equally well, mainly targets a region between residues 274 and 282. This region appears well defined in the BDBV335 EM map, indicated by the large lobe on the outside of the glycan cap that closely resembles that region in the GP crystal structure. When viewed along the 3-fold axis of GP, BDBV41 binds to the right of BDBV335, further up on the glycan cap, close to a loop that extends from residue 266 to 277. Consistent with this position, we passaged a chimeric VSV in which the G protein was replaced with BDBV GP as a sole surface protein (VSV/BDBV-GP) in the presence of mAb BDBV41 to generate a neutralization escape mutant virus that was completely resistant to the antibody and that possessed two amino acid substitutions, G271R and T272S ( Figure S5 ). The mutation at the 272 position likely explains why BDBV41 is a group 1 antibody, i.e., only recognizes BDBV (with T272), but not EBOV or SUDV (which have the alternate residue K272). BDBV41 also may make contacts with a loop that extends toward the mucin-like domains, from residue 309 to 312 or further in regions that were unresolved in the GP crystal structure. BDBV432 binds to the left of BDBV335, at the top of a helix loop at residues 259-266, and likely makes extensive contacts with a loop from residues around 302-312. Despite a lack of binding to sGP, BDBV432, as well as BDBV353, binds in the glycan cap region, suggesting that these mAbs make contacts with residues that are exclusive to GP. The other antibodies in group 1B bind to an epitope at the base of GP. These antibodies, including BDBV255 and BDBV259, bind further down on GP than has been observed previously with murine mAbs, possibly contacting residues within GP2 that are part of the membrane proximal external region (MPER) (Figures 4C-4E ). These antibodies were refractory to a reconstruction by EM due to predominant side views of the particles and also apparent flexibility. The class averages, however, clearly show that these antibodies bind an epitope that extends down below the base of GP. Three Fabs can be seen in some of the class averages, indicating that despite the apparent small size of this region, three antibodies can be accommodated on one GP trimer. Although the Fabs adopt various positions in each class average, there is not a continuous range of flexibility (A) Shown are negative-stain EM reference-free 2D class averages of group 1A antibodies that bind both the glycan cap of GP and sGP, and group 1B antibodies that bind the glycan cap of GP, but not sGP. BDBV GP or GPDmuc was used to generate complexes. (B) 3D reconstructions of glycan cap binders from groups 1A and 1B reveal that these antibodies bind the glycan cap at overlapping but distinct epitopes. Top (left) and side (right) views of the complexes are shown. (C) Reference-free 2D class averages of group 1B antibodies (left) reveal that these antibodies bind an epitope below the base of GP that is flexible. In the middle image, GP is colored yellow and each Fab is colored green. The righthand panel illustrates a superimposition of crystal structures of SUDV GPDmuc (PDB: 3VE0) and Fabs (PDB: 3CSY) to demonstrate how Fabs may bind to GP. (D) The composite model delineates the epitopes of the glycan cap mAbs in group 1A or 1B. Side (above) and top (below) views are shown. (E) Docking a crystal structure of SUDV GPDmuc (PDB: 3VE0) (Bale et al., 2012) , which contains a more complete model of the glycan cap region targeted by group 1A/B mAbs, reveals how group 1A/B mAbs target a broad region in the GP1 centered on the glycan cap, near the beginning of the mucin-like domains. Group 1B mAbs that target the base likely bind to a loop near the membrane proximal external region (MPER) that is flexible and has not yet been resolved at high resolution. TM, transmembrane region; CT, cytoplasmic tail. See also Figure S4. since the Fabs themselves are well resolved. These antibodies may require the full MPER and transmembrane (TM) regions, as well as a membrane, in order to bind stably. These features are all lacking in the current recombinant protein used here, a soluble form of the extracellular domain of GP. While the GP2 region is well conserved across the filoviruses, these BDBV-specific mAbs likely bind non-conserved regions in GP2 proximal to the TM region.
Epitope Mapping of Group 3A mAbs Using Saturation Mutagenesis and Negative-Stain EM As the group 3A (cross-reactive) nAbs competed for binding with group 1A (BDBV-specific) nAbs (Figure 3) , we hypothesized that some structural features of the glycan cap are conserved among GPs from multiple Ebolavirus species. We sought to identify critical amino acids that defined epitopes for three group 3 nAbs (BDBV270, BDBV289, and BDBV324) using a comprehensive EBOV GP alanine-scanning mutation library (Davidson et al., 2015) . Epitope mapping identified critical residues for binding by each nAb as follows: W275 for BDBV270, W275 and Y241 for BDBV289, and W275 and L273 for BDBV324. Residues for which mutation reduced binding of three nAbs from group 3A were visualized on the surface of the high-resolution structure of EBOV GP (PDB: 3CSY). This finding suggests that each of these antibodies recognizes overlapping epitopes in the GP glycan cap (Figures 5A and 5B). The previously described murine nAbs 2G4 and 4G7 and the human nAb KZ52 were shown previously to bind the base region of the GP (Lee et al., 2008; Murin et al., 2014) , and mutations of the W275 or L273 residue did not reduce the binding of these nAbs ( Figure 5C ). We passaged VSV/BDBV-GP in the presence of BDBV223 or BDBV289 in an attempt to generate escape mutant viruses, but could not detect (A and B) Epitope residues for three nAbs from group 3A (BDBV270, BDBV289, and BDBV324) were identified as those for which mutation to alanine specifically reduced binding of these antibodies. GP residue W275 was common to all three nAbs, while L273 was specific for BDBV324 and Y241 was specific for BDBV289. The mutated residues are shown in space-filling forms on a ribbon diagram of the EBOV GP structure, based on PDB: 3CSY. (C) Binding values for nAbs and previously isolated mAbs KZ52, 2G4, and 4G7 to library clones with mutations at residues L273, W275, and Y241. The Ab reactivities against each mutant EBOV GP clone were calculated relative to reactivity with wild-type EBOV GP. (D) BDBV289 (brown) binds at the top of the viral GP near the glycan cap region. Complexes are of BDBV antibody Fab fragments bound to BDBV GPDTM with side view (top panel) or top view (bottom panel). A representative Fab crystal structure is fit in the Fab density for each reconstruction (from PDB: 3CSY). A monomer of the GP trimer crystal structure (PDB: 3CSY) is also fit in the GP density, with white corresponding to GP1 and black to GP2. Two critical residues for binding by BDBV289 (W275 and Y241, determined using saturation mutagenesis) are highlighted in green. See also Figure S5 .
neutralization-resistant viruses. An isolate passaged in the presence of BDBV223 with a R574H polymorphism in heptad repeat 1 (HR1) region was identified, and for BDBV289 an isolate with an I584M polymorphism in the HR1 region alone or in combination with an E149K substitution in the receptor-binding domain was identified. However, none of these mutations was associated with the ability of those viruses to resist neutralization by the corresponding mAb. We further characterized BDBV289 by single-particle EM studies of antibody in complex with GP. BDBV289 binds the glycan cap region of GP, centered on the residues W275 and Y241 ( Figures 5D and S4 ). The angle of approach resembles that of the mAb 1H3 from the antibody cocktail ZMab, although 1H3 is specific to EBOV and is weakly neutralizing (Murin et al., 2014; Qiu et al., 2011) . Further, BDBV289 also binds sGP, which shares the first 295 amino acids of GP1 with GP, including the glycan cap region (Sanchez et al., 1996; Volchkov et al., 1995) . Therefore, despite previous hypotheses that propose that sGP is an immune decoy and that cleavage of the glycan cap prevents neutralizing antibodies from binding this region (Mohan et al., 2012; Murin et al., 2014) , we have now identified several antibodies that challenge these ideas. Interestingly, BDBV289 targets an overlapping epitope with antibodies that we identified to be specific to BDBV and that do not bind sGP (Figure 4) . Therefore, the glycan cap region is a major antigenic site that contains epitopes with subtle features that influence sGP and GP binding, neutralization, and species cross-reactivity of targeting mAbs.
Therapeutic Efficacy of Human mAbs in Small Animal Models of EBOV Infection
To determine the therapeutic activity of cross-neutralizing Abs, we tested several antibodies in mice. We focused on cross-reactive antibodies, and we studied the heterologous effect of BDBV survivor mAbs against EBOV challenge. We selected two nAbs from groups 3A (BDBV289) and 3B (BDBV223) that bound nonoverlapping antigenic regions in the competition-binding experiments (Figure 3) . The 7-week-old BALB/c mice received 100 mg antibody by the intraperitoneal (i.p.) route 1 or 3 days after inoculation with 1,000 plaque-forming units (PFUs) of mouse-adapted EBOV, strain Mayinga (Bray et al., 1998) . BDBV223 and BDBV289 reduced disease and protected mice from death when delivered 1 day after challenge with EBOV ( Figure 6 ). We did not observe a therapeutic effect in the mice receiving the antibodies 3 days after the challenge.
Finally, we set out to test in vivo efficacy of the cross-reactive nAbs BDBV289 and BDBV223 using a guinea pig model of EBOV infection. The 5-to 6-week-old guinea pigs, strain Hartley, were injected with 5 mg antibody by the i.p. route once (day 1) or twice (days 1 and 3) after inoculation with 1,000 PFU of guinea pigadapted EBOV, strain Mayinga. BDBV223 provided marginal protection, as only one of five animals survived the lethal challenge (Figure 7) . Surprisingly, a glycan cap-specific nAb, BDBV289, fully protected guinea pigs when delivered twice after the virus challenge. The protective efficiency of BDBV289 with a single treatment against a heterologous EBOV (Figure 7 , three of five animals survived) was higher than the protective efficiency of the equivalent glycan-cap-specific mAb c13C6, a component of the ZMapp cocktail (one of six animals survived) . To determine whether a combination of two mAbs that target two neutralizing epitopes on the EBOV GP surface confer better protection than treatment with a single mAb alone, we tested the combination of BDBV223 and BDBV289 in guinea pigs. The combination of two antibodies provided complete protection against a heterologous EBOV with only a single treatment ( Figure 7 ). We isolated viral RNA from blood of representative animals that were treated with mAbs BDBV223 or BDBV289 but died, and then sequenced the genes encoding the GP (Table S2 ). Several polymorphisms were detected, but none appeared to be directly related to the epitope specificity of the mAb used for treatment.
DISCUSSION
This study reveals that natural BDBV infection in humans triggers the development of ebolavirus cross-reactive antibodies that target epitopes on the GP surface that are conserved in diverse species of genus Ebolavirus. During these studies, we isolated 90 human mAbs from humans following BDBV infection and found 57 cross-reactive mAbs that recognized heterologous EBOV GPs. Remarkably, some of the isolated cross-reactive mAbs not only bound but also neutralized multiple Ebolavirus species. The majority of cross-reactive mAbs neutralized BDBV and EBOV, but we also isolated two antibodies that displayed potent neutralizing activity against representatives of three Ebolavirus species, BDBV, EBOV, and SUDV. We tested two cross-neutralizing mAbs in mice and guinea pigs and showed that they protected animals from lethal challenge with a heterologous species of EBOV. These data suggest that cross-neutralizing mAbs can be used to develop a universal treatment against multiple ebolaviruses, and they imply that highly immunogenic vaccines with proper presentation of GP from one species could induce some measure of cross-protection against viruses of the other species. The ability of these mAbs to bind and neutralize a broad range of Ebolavirus species also suggests that such antibodies might offer protection against emerging filoviruses in the future. Our study highlights the neutralization and protective potencies of human glycan cap-specific antibodies. It has been suggested previously that glycan cap-binding mAbs may not neutralize well because cathepsins remove this region during viral entry (Murin et al., 2014) . However, several of the BDBV glycan cap-specific mAbs isolated here exhibit very potent neutralizing activity, and they recognize diverse epitopes within this major antigenic site. Furthermore, a single glycan cap-specific nAb, BDBV289, provided complete protection in EBOV-challenged guinea pigs. The mechanism used by glycan cap-binding mAbs to neutralize the virus in vitro is unclear. The glycan cap-specific antibodies described here bind to sites distant from the putative cathepsin cleavage site (located at residue 190), so they are unlikely to interfere with GP cleavage. While the amino acid sequence of the GP1 region is generally less well conserved than that of GP2 in viruses of diverse filovirus species, the five neutralizing glycan cap mAbs studied with EM imaging here target conserved residues, indicating that these regions may be important to the viral life cycle. Therefore, these mAbs may block some yet undefined function of the glycan cap.
Several antibody-based treatments provided a complete species-specific protection from EBOV in a non-human primate model of infection . However, antibody-based therapeutics against other members of the Ebolavirus genus, such and BDBV and SUDV, are not yet available. While one strategy would be to develop separate antibody treatments for each filovirus infection, an alternative strategy would be to have a universal treatment effective against diverse Ebolavirus species. The development of universal antibody treatments for ebolaviruses seems inevitable, given recent progress in the identification of broad and potent neutralizing antibodies against viruses that exhibit more antigenic diversity than the filoviruses such as HIV (Burton et al., 2012) , influenza viruses (Pappas et al., 2014) , dengue virus (Rouvinski et al., 2015) , alphaviruses (Fox et al., 2015) , and paramyxoviruses (Corti et al., 2013) . Our results provide a roadmap to develop a single antibody-based treatment effective against multiple Ebolavirus infections. We propose that the principal components of such treatment should include cross-neutralizing mAbs that target conserved elements of the non-overlapping major neutralizing antigenic sites on the GP surface.
EXPERIMENTAL PROCEDURES Donors
De-identified peripheral blood mononuclear cells (PBMCs) from seven survivors of the 2007 BDBV outbreak in Uganda (Towner et al., 2008) were obtained from a repository at Makerere University (Kampala, Uganda) managed in collaboration with the U.S. Military HIV Research Program MHRP, which is part of the Walter Reed Army Institute of Research. PBMCs were obtained after informed consent from a U.S. survivor of EBOV infection who was infected while delivering health care in Liberia during the 2014 Ebola virus outbreak with Makona virus. Cells from the EBOV survivor were obtained about 11 weeks after infection and about 7 weeks after discharge from hospital, following several negative PCR tests for presence of virus. PBMCs were obtained from a U.S. survivor of MARV infection who developed the disease in early 2008 following exposure to fruit bats in the Python Cave in Queen Elizabeth National Park, Uganda. This donor's clinical course was documented previously (Centers for Disease Control and Prevention, 2009), and we have reported previously on isolation of human antibodies from this donor . Peripheral blood from the donor was obtained in 2012, 4 years after the illness, following informed consent. The studies were approved by the Vanderbilt University Institutional Review Board.
Viruses BDBV strain 200706291 Uganda was isolated originally from the serum of a patient during the first recorded outbreak caused by this virus (Towner et al., 2008) 
Generation of Human Hybridomas Secreting mAbs
Human hybridomas were generated as described previously . In brief, previously cryopreserved samples were transformed with Epstein-Barr virus, CpG, and additional supplements. After 7 days, cells from each well of the 384-well culture plates were expanded into four 96-well culture plates using cell culture medium containing irradiated heterologous human PBMCs (recovered from blood unit leukofiltration filters, Nashville Red Cross) and incubated for an additional 4 days. Plates were screened for BDBV GP antigen-specific antibody-secreting cell lines using ELISAs. Cells from wells with supernates reacting with antigen in an ELISA were fused with HMMA2.5 myeloma cells using an established electrofusion technique (Yu et al., 2008) .
Human mAb and Fab Production and Purification
After fusion, hybridoma cell lines were cloned by single-cell fluorescenceactivated cell sorting and expanded in post-fusion medium as previously described . HiTrap Protein G or HiTrap MabSelectSure columns were used to purify antibodies from filtered supernates. Fab fragments were generated by papain digestion, as described previously .
Expression and Purification of Filovirus GPs
BDBV GP ectodomain (BDBV GP, residues 1-637) or the sGP dimer (BDBV sGP, residues 1-316) was used to screen supernatants of transformed B cells. Recombinant GPs were engineered with a C-terminal double strep tag and cloned into a modified pMTpuro vector for expression in Drosophila S2 cells. Briefly, plasmids were transfected into S2 cells using Effectene reagent (QIAGEN) followed by stable cell selection with 6 mg/ml puromycin. S2 cells first were cultured in Schneider's medium supplemented with 10% (v/v) fetal calf serum (FCS, Lonza), and later they were adapted to Insect Xpress medium for large-scale expression in 2-l shaker flasks. Stable cells were induced with 0.5 mM CuSO 4 and harvested after 4 to 5 days at 27 C. Tangential flow filtration then was used to buffer exchange the supernatants into 100 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, and 15 mg/ml avidin (pH 8.0), and target proteins were purified using Streptactin Superflow affinity (QIAGEN). GP ectodomains were purified further with S200 size exclusion chromatography (SEC); sGP was purified with S75 SEC. Recombinant ectodomains for EBOV, SUDV, or MARV were designed and expressed similarly.
Screening and EC 50 ELISA-Binding Analysis Soluble forms of the full-length extracellular domain of BDBV, EBOV, SUDV, or MARV GPs or the sGP form of BDBV GP were coated overnight onto 384-well plates at 1 mg/ml. For screening ELISA, 10 ml supernate from a well of a tissueculture plate was transferred to each well of a 384-well ELISA plate. For EC 50 -binding analysis by ELISA, purified antibodies were applied to the plates at a concentration range of 30 mg/ml to 170 ng/ml, using 3-fold serial dilutions. The presence of antibodies bound to the GP was determined using goat anti-human IgG alkaline phosphatase conjugate and p-nitrophenol phosphate substrate tablets, with optical density read at 405 nm after 120 min. A nonlinear regression analysis was performed on the resulting curves using Prism version 5 (GraphPad) to calculate EC 50 values. The Circos software package was used for data visualization (Krzywinski et al., 2009 ).
EBOV and MARV Neutralization Experiments
Isolated mAbs were screened initially in a high-throughput neutralization assay using EBOV/BDBV-GP with or without 5% guinea pig complement (MP Biomedicals) (P.A. Ilinykh, unpublished data). The mAbs that exhibited neutralizing activity also were screened for neutralization of EGFP-expressing EBOV (Towner et al., 2005 ). Several mAbs were tested for neutralization of EBOV/SUDV-GP and EBOV/MARV-GP by the same approach. Additional information is given in the Supplemental Experimental Procedures.
Biolayer Interferometry Competition-Binding Assay
Competition binding studies using biolayer interferometry and biotinylated BDBV GP (EZ-link Micro NHS-PEG 4 -Biotinylation Kit, Thermo Scientific 21955) (5 mg/ml) were performed on an Octet RED biosensor (ForteBio), as described previously . In brief, the antigen was immobilized onto streptavidin-coated biosensor tips. After a brief washing step, biosensor tips were immersed first into the wells containing first antibody at a concentration of 100 mg/ml and then into the wells containing a second mAb at a concentration of 100 mg/ml. The percentage binding of the second mAb in the presence of the first mAb was determined by comparing the maximal signal of the second mAb applied after the first mAb complex to the maximal signal of the second mAb alone.
Sequence Analysis of Antibody Variable Region Genes
Antibody variable gene sequence analysis was performed as previously described . Heavy-chain antibody variable region sequences were analyzed using the IMGT/V-Quest program (Brochet et al., 2008; Giudicelli et al., 2011) .
EM and Sample Preparation
Fabs were added in 10 M excess to BDBV GPdMuc and subsequently purified and stained as previously described (Murin et al., 2014) .
Image Processing of Protein Complexes
Particles were automatically picked using DoG Picker ) and particle stacks were generated using Appion (Lander et al., 2009 ). Subsequently, reference-free two-dimensional (2D) class averages were generated using iterative multi-reference alignment (MRA)/multivariate statistical analysis (MSA) (van Heel et al., 1996) . Non-GP complexes and those with a clear lack of full saturation by Fab were removed to generate a final stack for reconstructions. In some cases, orientation bias or flexibility of Fabs prevented convergence of an acceptable model, although examination of class averages allowed a general assignment of the epitope. Final stack class averages were used to generate initial models using EMAN2 common lines (Tang et al., 2007) . A model matching its reference projections was further refined using the entire raw particle stack with EMAN2, as described previously (Murin et al., 2014) . For the BDBV41 reconstruction, the EMAN2 reconstruction lacked important features that were present in the class averages, indicating that perhaps some particles lacked full Fab saturation. To circumvent this problem, we utilized the Relion package, which allows three-dimensional (3D) classification to remove particles that may only contain two Fabs, significantly improving the quality of the final EM map (Scheres, 2012) . Modeling fitting and EM figures were generated using UCSF Chimera (Pettersen et al., 2004) .
Epitope Mapping Using an EBOV GP Alanine-Scan Mutation Library
Comprehensive high-throughput alanine scanning (shotgun mutagenesis) was carried out on an expression construct for EBOV GP (Yambuku-Mayinga variant GP; UniProt: Q05320) (Davidson et al., 2015) . Additional details are reported in the Supplemental Experimental Procedures.
In Vivo Testing
The animal protocols for testing of mAbs in mice and guinea pigs were approved by the Institutional Animal Care and Use Committee of the UTMB. The 7-week-old BALB/c mice (Charles River Laboratories) were placed in the ABSL-4 facility of the Galveston National Laboratory. Groups of mice at five animals per group were injected with 1,000 PFU of the mouse-adapted EBOV by the i.p. route. Then 24 or 72 hr later, animals were injected with individual mAbs by the i.p. route using 100 mg per treatment. Animals treated with the antibody specific to dengue virus 2D22 served as controls. Animals were weighed and monitored daily over the 2-week period after challenge. Once animals were symptomatic, they were examined no less than twice per day. The disease was scored using the following parameters: dyspnea (possible scores 0-5), recumbency (0-9), unresponsiveness (0-5), and bleeding/hemorrhage (0-5). To test the protective efficacy of mAbs in guinea pigs, five-to sixweek-old animals (strain Hartley) were placed in the ABSL-4 facility of the Galveston National Laboratory. Groups of five animals per group were injected with 1,000 PFU of guinea pig-adapted EBOV by the i.p. route. Then 24 or 24 and 72 hr later, animals were injected with individual mAbs (5 mg per treatment) or a cocktail of two mAbs (2.5 mg of each mAb per treatment). Animals were weighed and monitored daily for 28 days. After animals became symptomatic, they were examined no less than twice per day. The disease was scored using the following parameters: appearance (possible scores 0-3), body condition (0-3), natural behavior (0-3), and provoked behavior (0-3).
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